Sogorb-Esteve, A;
Garcia-Ayllon, M-S;
Llansola, M;
Felipo, V;
Blennow, K;
Saez-Valero, J;
(2018)
Inhibition of gamma-Secretase Leads to an Increase in Presenilin-1.
Molecular Neurobiology
, 55
(6)
pp. 5047-5058.
10.1007/s12035-017-0705-1.
Preview |
Text
Sogorb-Esteve2018_Article_InhibitionOfΓ-SecretaseLeadsTo.pdf - Published Version Download (1MB) | Preview |
Abstract
γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven disappointing. We addressed the possibility that γ-secretase inhibition can provoke a rebound effect, elevating the levels of the catalytic γ-secretase subunit, presenilin-1 (PS1). Acute treatment of SH-SY5Y cells with the GSI LY-374973 (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, DAPT) augments PS1, in parallel with increases in other γ-secretase subunits nicastrin, presenilin enhancer 2, and anterior pharynx-defective 1, yet with no increase in messenger RNA expression. Over-expression of the C-terminal fragment (CTF) of APP, C99, also triggered an increase in PS1. Similar increases in PS1 were evident in primary neurons treated repeatedly (4 days) with DAPT or with the GSI BMS-708163 (avagacestat). Likewise, rats examined after 21 days administered with avagacestat (40 mg/kg/day) had more brain PS1. Sustained γ-secretase inhibition did not exert a long-term effect on PS1 activity, evident through the decrease in CTFs of APP and ApoER2. Prolonged avagacestat treatment of rats produced a subtle impairment in anxiety-like behavior. The rebound increase in PS1 in response to GSIs must be taken into consideration for future drug development.
| Type: | Article |
|---|---|
| Title: | Inhibition of gamma-Secretase Leads to an Increase in Presenilin-1 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s12035-017-0705-1 |
| Publisher version: | https://doi.org/10.1007/s12035-017-0705-1 |
| Language: | English |
| Additional information: | © The Author(s) 2017. Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| Keywords: | Alzheimer’s disease, Presenilin-1, γ-Secretase inhibitor, Therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10065950 |
Archive Staff Only
 |
View Item |
